Isolated immune cell populations support a wide variety of research and cell therapy applications. Because purification and preliminary characterization of immune cell subsets can be time-consuming and costly, many researchers prefer to purchase isolated immune cells rather than raw materials.
You wanted cell isolation – we delivered!
In 2021, the word isolation tends to have garnered a negative connotation. However, when a cell biologist thinks of isolation, specifically cell isolation, they think of it as a wonderful thing.
After all, isolated cells are a sought-after starting material that allows scientists to dive deeper into their research and accelerate their studies. At HemaCare, we heard your requests and can now deliver isolated immune cells from full leukopak collections to your doorstep!
New webinar highlights the benefits of “dedicated donor pools” - the latest offering from HemaCare to accelerate successful cell therapy research and commercialization
HemaCare, through Charles River Labs, recently hosted an educational webinar focused on their latest cell and gene therapy-related service.
HemaCare will now be working with clients to establish “dedicated donor” pools. The purpose of this new program is to establish and maintain a pool of reliable, recallable donors with client-determined physiological and/or demographic characteristics that match specific client research projects and programs.
A new study that was led by scientists at the La Jolla Institute for Immunology showed that healthy people can have predatory CD8+ T cells in their pancreases, and in high numbers.
Type 1 diabetes (T1D) develops when the body’s own immune system destroys the pancreatic beta cells. Breakdown in peripheral tolerance and compromised thymic selection have been thought to be associated with the development of T1D. However, the results of a recent study challenge this belief.
Pharmaceutical giant Pfizer cite the use of HemaCare starting materials in the development of a new immune cell validation assay. 
The new assay is designed to measure dendritic cell activation as a predictor of immunogenicity, so that scientists can assess risk early in the development of new pharmaceuticals. Low immunogenicity points toward a better overall safety profile.
Dendritic cells (DC) are antigen-presenting cells, involved in the initiation and regulation of the immune response. Since DC are tumor-infiltrating cells central to the initiation of antigen-specific immunity, they have long been investigated as a means of improving cancer immunotherapy.